Insulet Corporation Revenue and Competitors

Claim your profile

Boston, MA USA

Location

$129.5M

Total Funding

Estimated Revenue & Valuation

  • Insulet Corporation's estimated annual revenue is currently $1B per year.(i)
  • Insulet Corporation received $340.2M in venture funding in November 2017.
  • Insulet Corporation's estimated revenue per employee is $322,781
  • Insulet Corporation's total funding is $129.5M.
  • Insulet Corporation's current valuation is $16.7B. (January 2022)

Employee Data

  • Insulet Corporation has 3222 Employees.(i)
  • Insulet Corporation grew their employee count by 11% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$3.8M370%N/AN/A
#2
$3M2938%N/AN/A
#3
$4M167%N/AN/A
#4
$4.5M18-25%N/AN/A
#5
$5630M81806%$450MN/A
#6
$4M167%N/AN/A
#7
$5.8M4612%$29.6MN/A
#8
$12.6M5043%N/AN/A
#9
$1.9M15-17%$44MN/A
#10
$54.6M212-9%N/AN/A

About Insulet Corporation: Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod, by tailoring its Omnpod technology platform for the delivery of non-insulin subcutaneous drugs across multiple therapeutic areas. Founded in 2000, more than 100,000 users across the globe rely on Insulet's Omnipod Insulin Management System to bring simplicity and freedom to their lives. For more information, please visit: www.insulet.com, www.myomnipod.com and https://www.omnipodeurope.com.* *Starting July 1, 2018, Insulet will assume direct distribution of its Omnipod Insulin Management System in Europe, including sales, marketing, training and customer support activities. This will allow Insulet to be closer to the diabetes community and identify opportunities to support European customer needs over the long term, as it already does in the United States and Canada.

keywords:Biotechnology,Healthcare,Medical Devices

$129.5M

Total Funding

3222

Number of Employees

$1B

Revenue (est)

11%

Employee Growth %

$16.7B

Valuation

N/A

Accelerator

Insulet Corporation News

2022-04-19 - Insulet (PODD) to Release Quarterly Earnings on Thursday

Analysts expect the company to announce earnings of $0.24 per share for the quarter. Insulet has set its Q1 2022 guidance at EPS and its FY...

2022-04-17 - Insulet Presents New Omnipod® 5 System Data for Type 1 ...

BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its...

2022-04-17 - Insulet Co. (NASDAQ:PODD) Expected to Post Quarterly ...

Several equities research analysts have weighed in on the company. UBS Group upgraded Insulet from a “neutral” rating to a “buy” rating and...

2019-09-14 - Assessing If Insulet Corporation Has Started An Intermediate ...

Shares of Insulet Corporation (PODD) (The Insulin Provider) for example have been on a relentless rally since they bottomed in 2009.

2019-09-12 - Checklist Stock of the Day : Insulet Corporation (PODD)

Insulet Corporation (PODD):. If you are considering getting into the day trading or penny stock market, it's a legitimate and profitable method for ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2360M388710%$22.5M
#2
$700M451610%N/A
#3
$2180M609010%N/A

Insulet Corporation Funding

DateAmountRoundLead InvestorsReference
2002-10-07$22.0MSpending On: UndisclArticle
2004-03-03$35.5MUndisclosedAlta PartnersArticle
2006-02-17$50.0MUndisclosedThe Federated Kaufman FundArticle
2009-03-17$60.0MUndisclosedDeerfield Management CompanyArticle
2016-09-07$250.0MUndisclosedArticle
2017-11-09$340.2MUndisclosedArticle